Chemical subgroup
S01LA – Antineovaskuläre Mittel
11Decisions
12Patient groups
Added benefit by patient group
- Not proven12
Decisions, newest first
- 2025-10-16LytenavaBevacizumabNot proven
- 2025-02-20VabysmoFaricimabNot proven: 2 of 2 patient groups
- 2024-05-02BeovuBrolucizumabNot proven
- 2023-04-06VabysmoFaricimabNot proven
- 2023-04-06VabysmoFaricimabNot proven
- 2022-10-20BeovuBrolucizumabNot proven
- 2016-05-19EyleaAfliberceptNot proven
- 2015-09-03EyleaAfliberceptNot proven
- 2015-03-05EyleaAfliberceptNot proven
- 2014-03-20EyleaAfliberceptNot proven
- 2013-06-06EyleaAfliberceptNot proven
Data status: 2026-10-29